When Employees Ask About Weight-Loss Drugs: Reading the Obesity Clauses in an Indian Group Mediclaim

Three reports in ten days said the same thing about American employers. People Matters reported on 26 August 2026 that PepsiCo will end weight-loss drug coverage for some employees as healthcare costs rise. Reuters reported on 28 August 2026 that more US employers plan to drop the drugs in 2027. SHRM followed on 1 September 2026 on the growing number dropping GLP-1 coverage outright.

Indian employers read that coverage and ask their brokers what the group mediclaim says about these drugs. The answer, in almost every case, is nothing. There is no GLP-1 position in an Indian group wording to retreat from, because the wordings were drafted around a hospitalisation indemnity that never contemplated a chronic self-administered injectable.

The question still has to be answered, because employees are asking. Semaglutide and tirzepatide are both available on prescription in India, marketed by their originators since 2025, and the Indian product patent on semaglutide lapsed in March 2026, opening the way to generic supply. When the ask reaches the broker, three clauses half-answer it: the standard obesity exclusion, the outpatient pharmacy sub-limit, and whatever weight-control exclusion the insurer filed with the product.

The obesity exclusion in an Indian health wording is standardised. The IRDAI Guidelines on Standardization of Exclusions in Health Insurance Contracts, 2019 fixed uniform text for a set of permitted exclusions, and obesity sits at Code Excl 06. The code is headed "Obesity/Weight Control", which is where the misreading starts, because the operative text under that heading reads:

Expenses related to the surgical treatment of obesity that does not fulfil all the below conditions: 1. Surgery to be conducted is upon the advice of the Doctor. 2. The surgery/Procedure conducted should be supported by clinical protocols. 3. The member has to be 18 years of age or older. 4. Body Mass Index (BMI) greater than or equal to 40, or greater than or equal to 35 in conjunction with any of the following severe co-morbidities following failure of less invasive methods of weight loss: obesity-related cardiomyopathy, coronary heart disease, severe sleep apnea, or uncontrolled Type 2 Diabetes.

Read it as drafted. Excl 06 is a conditional exclusion of surgery. It removes bariatric procedures from cover unless four tests are met, and where they are met the procedure is payable. It says nothing about a drug, because in 2019 the obesity question in an Indian wording was a bariatric question.

Two consequences follow, and they point in opposite directions.

• An insurer cannot cleanly decline a GLP-1 claim by citing Excl 06. The code addresses surgical treatment, and a prescription for a weekly injectable is not that.
• Nothing in Excl 06 grants cover either. A clause silent on drugs is not an inclusion of drugs. The grant has to come from elsewhere in the policy wording, and usually it does not exist.

Where an insurer wants a wider obesity position than the standard code gives it, that has to appear as its own filed exclusion in the specific-exclusions annexure rather than as extra words bolted onto the standard code. Language along the lines of "treatment, drugs or programmes for weight reduction or weight gain", or "obesity and its consequences", changes the answer completely and is easy to miss, because it sits below the standardised block that everyone skims.

Even where no weight-control exclusion exists, the structure of the product settles the question. A group mediclaim is an indemnity contract triggered by a 24-hour inpatient admission, extended by a defined day-care procedure list and by the standard 30-day pre-hospitalisation and 60-day post-hospitalisation windows. A GLP-1 course is none of those events. It is a retail pharmacy purchase, self-injected at home, repeated weekly for months or years, with no admission anywhere in the sequence.

That leaves one route by which the base policy touches the drug. Where a member has a payable admission and the treating doctor prescribes the medication as part of that episode, the drug can fall inside the post-hospitalisation window for sixty days and no longer. A prescription written after bariatric surgery or a cardiac admission is the realistic case. It is a sixty-day tail on a therapy measured in years, so it changes little about the employee's economics and nothing about the employer's.

This is the part HR teams get wrong most often. They assume the fight is about an exclusion when it is about a trigger. Deleting the exclusion would not make an outpatient pharmacy bill payable under a hospitalisation contract.

If a group programme is going to pay for obesity pharmacotherapy, it will be through an OPD benefit, either an insured rider on the group mediclaim or an employer-funded wallet. That is where the numbers stop working.

Insured OPD riders in the Indian market are typically written at annual limits around Rs 10,000 per employee, and employer-funded wallets at Rs 8,000 to 15,000, often with a pharmacy sub-limit that is a fraction of the headline figure. Branded GLP-1 therapy at Indian retail prices runs to a five-figure rupee sum every month at maintenance doses. A full year of the OPD benefit funds roughly one month of the drug.

The pricing problem is worse than the shortfall suggests. OPD riders are underwritten on the assumption that members draw on a small limit episodically, and that a meaningful share of the limit across the pool goes unused. A member on continuous GLP-1 therapy consumes 100% of the limit with certainty, in the first weeks of the policy year, every year. That is a budget line dressed as a claim, and it reprices at renewal.

Generic supply pulls the same way rather than the opposite one. Cheaper units do not reduce programme cost when the binding constraint is take-up. They lower the threshold at which an employee decides the therapy is worth starting, which raises the number of members drawing the full limit.

The three reports from late August and early September 2026 are worth reading for the mechanism rather than the verdict. Employers dropping GLP-1 cover are not concluding that the drugs do not work. They are responding to a shape of spend that group health products handle badly.

Medical insurance prices low-frequency, high-severity events. GLP-1 therapy is the reverse in every dimension that matters to a pricing actuary. Eligibility is broad, take-up is elective, adherence is the point rather than an incident, no clinical event ends the claim, and discontinuation tends to reverse the benefit, which argues for indefinite continuation. Cost scales with how many members enrol, not with how unlucky the pool is. PepsiCo's decision and the wider 2027 withdrawals are what happens when a benefit priced as insurance behaves as a subsidy.

The part that transfers least well to India is the control layer. American programmes ran GLP-1 cover through pharmacy benefit managers with prior authorisation, documented BMI thresholds, step therapy and mandatory enrolment in a lifestyle programme, and still saw cost run ahead of forecast. Indian group health has no equivalent apparatus. TPAs adjudicate hospitalisation claims and reimburse outpatient bills against prescriptions; they do not run utilisation management on retail pharmacy.

An Indian employer copying an open GLP-1 benefit therefore inherits the American cost curve without the American controls. If the benefit is granted at all, the gating has to be written into the endorsement, because no downstream administrator will supply it.

There is no default that avoids a decision. Silence is a position too, and it is the one that produces the worst employee experience.

1. Stay silent. The wording carries Excl 06 and no OPD pharmacy grant, and nobody says anything. Employees discover the answer through a rejected reimbursement and HR absorbs the complaint. The cost of this position is not premium, it is credibility.
2. Exclude explicitly, and say so. Confirm with the insurer that obesity pharmacotherapy is outside the programme, then state it in the benefit booklet in one plain sentence. This costs nothing and removes the surprise. Most mid-market employers should land here.
3. Grant a capped, clinically gated benefit. A per-member annual sub-limit inside the OPD benefit, gated on documented clinical criteria that mirror the Excl 06 tests (prescriber advice, a stated BMI threshold, comorbidity where the BMI is lower), with an annual review and the whole thing on the record as an endorsement to the policy. The cap is the product. Without one, the benefit is open-ended.
4. Move it outside the insurance contract. Fund a metabolic-health programme where the drug is one line alongside dietetics, monitoring and follow-up consultations, with a hard per-member rupee cap and a defined duration. This keeps the spend off the group mediclaim experience and lets the employer change the terms without an insurer negotiation.

Options three and four suit employers who have decided the benefit is worth buying, usually GCCs and large technology employers matching a global parent's programme. For everyone else, the honest answer is option two, delivered early rather than at a claim.

A group mediclaim is a one-year contract repriced annually on experience. Obesity pharmacotherapy is a multi-year therapy whose benefit reverses on discontinuation. Those two facts do not fit together, and the American withdrawals are the demonstration: employers that opened cover in one year are closing it in another, leaving members mid-course.

An Indian employer granting the benefit should draft the exit before it needs it. Three items belong in the endorsement or the internal benefit note.

• Sunset mechanics. Whether members already on therapy are grandfathered when the benefit is withdrawn, and for how long. A defined taper communicates better than an abrupt stop at 31 March.
• Experience segregation. Outpatient drug spend routed through the cash deposit account is money-routing, not risk transfer. Track it as a separate line from the hospitalisation burn so it does not contaminate the claim experience the insurer quotes on at renewal. An OPD benefit that runs hot returns as a hard GMC renewal twelve months later if the two are reported as one number.
• Voluntary tiers. Anti-selection is limited in a mandatory scheme where every employee is in. It is real in voluntary parent and dependent top-ups, where the members who buy up are the ones expecting to claim. Expect the insurer to price those tiers separately or decline the extension.

One cost point belongs in the business case. Employer-paid group health premium attracts 18% GST, so every rupee of insured benefit carries that loading on top of the insurer's expense and margin. Routing predictable drug spend through an insured rider is the most expensive way to deliver it, and the logic that makes an insured OPD rider poor value against a funded wallet applies with more force here, because the spend is not merely predictable, it continues for as long as the member stays on therapy.

Run this on the specimen wording and the benefits annexure together, before renewal terms are confirmed, and never on the sales deck.

1. Locate the obesity exclusion and confirm it carries the standard Excl 06 text without additions. Note whether the four bariatric conditions are reproduced accurately, since a wording that drops them has quietly narrowed the surgical cover too.
2. Read the specific-exclusions annexure below the standardised block for weight-reduction, weight-control, obesity-consequences or lifestyle-drug language. A real prohibition will be there.
3. Check whether an OPD benefit exists at all, and if it does, whether the eligible-expense definition covers prescription pharmacy or only consultations and diagnostics.
4. Identify the pharmacy sub-limit inside the OPD limit, in rupees, per member per year. Compare it against a realistic annual cost of therapy rather than a monthly one.
5. Confirm how the post-hospitalisation window treats medication prescribed at discharge, and for how many days.
6. Ask the insurer, in writing, how a GLP-1 claim prescribed for Type 2 diabetes is adjudicated against one prescribed for weight management. The answer belongs in the file, not in a phone call.
7. Decide the employer position from the four above and write it into the benefit booklet in language an employee can act on.
8. If the benefit is granted, get the cap, the clinical gate, the review date and the sunset terms into the endorsement rather than a side email.

The wider point holds beyond this molecule. Group health insurance wordings in India are built around admission, and the benefits employees now ask about sit outside admission: outpatient care, mental health, fertility, chronic medication. The parity failures in mental health wordings and the carve-back mechanics used for fertility cover are the same problem in different clauses. Obesity pharmacotherapy is the version that arrived this year, with a cost curve large enough that the answer should not be left to a claims adjudicator to improvise.